Login
Subscribe
Take a FREE Trial
About Us
Contact us
RSS
20 May 2013
Search
The Pharma Letter
Home
7 Day Premium Trial
Pharmaceuticals
Biotechnology
Generics
Events
Companies
Drugs
Subscribe
Invega Sustenna Articles
Alkermes and J&J initiate Ph III trial of three-month Invega Sustenna
12 June 2012
Showing 1-1 of 1 articles
1
Hot Topics
Most Read
Elan makes "transformational" acquisitions and a divestment
Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
New study shows UCB's Neupro reduces NSBP in RLS patient
Bristol-Myers' data on Yervoy and nivolumab causes a stir
Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
Elan makes "transformational" acquisitions and a divestment
Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
New study shows UCB's Neupro reduces NSBP in RLS patient
Bristol-Myers' data on Yervoy and nivolumab causes a stir
Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines